Get the Stockscreener App
7.31
2.14%
-0.15
Entrada Therapeutics Inc stock is traded at $7.31, with a volume of 71,697.
It is down -2.14% in the last 24 hours and up +5.95% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$7.46
Open:
$7.33
24h Volume:
71,697
Relative Volume:
0.19
Market Cap:
$285.02M
Revenue:
$5.74M
Net Income/Loss:
$-166.12M
P/E Ratio:
-1.8285
EPS:
-3.9978
Net Cash Flow:
$-131.64M
1W Performance:
+5.04%
1M Performance:
+5.95%
6M Performance:
-33.76%
1Y Performance:
+38.52%
1-Day Range:
$7.25
$7.56
1-Week Range:
$6.93
$7.765
52-Week Range:
$5.02
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
7.32 | 290.47M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
516.25 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.82 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.77 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.15 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.23 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-11-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Oppenheimer | Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
View All
Entrada Therapeutics Inc Stock (TRDA) Latest News
(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - TipRanks
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock - Investing.com
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620 - Bitget
Kush Parmar Sells 92,444 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares - MarketBeat
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M - Stock Titan
Entrada Therapeutics Inc (TRDA) Stock News Today - TradingKey
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Entrada Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Entrada Therapeutics Submits Q2 2026 10-Q Report to SEC - Kalkine Media
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entrada Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary - TradingView
Entrada Therapeutics Reports Second Quarter 2026 Financial Results - The Manila Times
Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M - TradingView
Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline - Stock Titan
Entrada Therapeutics director Kush Parmar sells $807,027 in shares By Investing.com - Investing.com India
5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com - Investing.com India
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
5am Ventures V sells $807,027 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics director Kush Parmar sells $807,027 in shares - Investing.com
Ventures L.P. 5Am Sells 114,756 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - marketbeat.com
Form 4 Entrada Therapeutics Inc For: 4 August By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing - marketscreener.com
Entrada Therapeutics (TRDA) holder sells shares, still reports 1.09M stake - stocktitan.net
Liquidity Mapping Around (TRDA) Price Events - Stock Traders Daily
Entrada Therapeutics Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Form 144 ENTRADA THERAPEUTICS For: 30 July By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. SEC Filing (Jul 30, 2026) - Stock Titan
Entrada Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entrada Therapeutics Inc (TRDA) Cash Flow - TradingKey
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entrada Therapeutics (TRDA) Climbs 5.47%: Support and Resistance in FocusSmart Money Flow Stocks - dars.gov.et
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Balance Sheet - TradingKey
Entrada Therapeutics Inc|Price:5.850|Chg%:-0.200 - TradingKey
Entrada Therapeutics (TRDA) Slides 3.33% as Stock Tests Key Support LevelsHigh Beta Stocks - dars.gov.et
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PARMAR KUSH | Director |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| PARMAR KUSH | Director |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
| 5AM Ventures V, L.P. | 10% Owner |
Jul 30 '26 |
Sale |
6.93 |
114,756 |
795,259 |
2,848,310 |
| 5AM Ventures V, L.P. | 10% Owner |
Jul 31 '26 |
Sale |
6.85 |
1,718 |
11,768 |
2,846,592 |
| PARMAR KUSH | Director |
Jul 30 '26 |
Sale |
6.93 |
114,756 |
795,259 |
2,848,310 |
| PARMAR KUSH | Director |
Jul 31 '26 |
Sale |
6.85 |
1,718 |
11,768 |
2,846,592 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):